Filing Flows › Supernus Pharmaceuticals (SUPN) › How it makes money
How Supernus Pharmaceuticals (SUPN) makes money
Supernus Pharmaceuticals (SUPN) made $227M of revenue in the third quarter 2026 (Q3 2026), +18% from a year earlier. Net product sales brought in $179M (79%); ONAPGO brought in $17.1M (8%); Trokendi XR brought in $10.2M (5%). Of every dollar of revenue, 9¢ was left as operating profit, 9¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Net product sales | $179M | 78.7% | +9% | +19% |
| ↳ Qelbree | $90.8M | 40.1% | +2% | +12% |
| ↳ GOCOVRI | $42.6M | 18.8% | +14% | +4% |
| ↳ Collaboration revenue (ZURZUVAE) | $41.7M | 18.4% | +18% | +107% |
| ↳ Other | $3.4M | 1.5% | +79% | -52% |
| ONAPGO | $17.1M | 7.5% | +26% | +151% |
| Trokendi XR | $10.2M | 4.5% | +21% | +2% |
| Oxtellar XR | $8.0M | 3.5% | -9% | -34% |
| Royalty, licensing, and other revenues | $6.5M | 2.9% | -64% | +91% |
| APOKYN | $6.5M | 2.9% | +3% | -38% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $227M | 100.0% |
| Operating profit | $21.2M | 9.3% |
| Income tax | $1.8M | 0.8% |
| Net earnings | $20.9M | 9.2% |
| Operating cash flow | $6.6M | 2.9% |
| Free cash flow | $6.4M | 2.8% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $227M | +18% |
| Q2 2026 | $219M | +32% |
| Q1 2026 | $208M | +39% |
| Q4 2025 | $212M | +22% |
| Q3 2025 | $192M | +9% |
| Q2 2025 | $165M | -2% |
| Q1 2025 | $150M | +4% |
From Supernus Pharmaceuticals' 10-Q filed Oct 29, 2026 (on EDGAR).
Questions
How does Supernus Pharmaceuticals make money?
Supernus Pharmaceuticals (SUPN) made $227M of revenue in the third quarter 2026 (Q3 2026), +18% from a year earlier. Net product sales brought in $179M (79%); ONAPGO brought in $17.1M (8%); Trokendi XR brought in $10.2M (5%). Of every dollar of revenue, 9¢ was left as operating profit, 9¢ was left as net earnings.
What is Supernus Pharmaceuticals' biggest business?
Net product sales: $179M in the third quarter 2026, 79% of revenue, +19% from a year earlier.
What is Supernus Pharmaceuticals' profit margin?
Net earnings were $20.9M, 9.2% of revenue, in the third quarter 2026; the operating margin was 9.3%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.